Please login to the form below

Not currently logged in

Immutep spikes on trial of its LAG-3 drug with Keytruda

Impressive mid-stage results in NSCLC and HNSCC


Shares in Australian biotech Immutep rose quickly on data for its cancer immunotherapy drug eftilagimod alpha alongside Merck & Co’s Keytruda in solid tumours.

Most of those gains dissipated after the results of the mid-stage trial in non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma of the (HNSCC) were presented at a conference in Germany in what appeared to be profit-taking.

The TACTI-002 trial is testing eftilagimod alpha or ‘efti’ in combination with Keytruda (pembrolizumab) in first and second-line NSCLC and second-line HNSCC, and demonstrated responses for the pairing across a range of patients with different levels of PD-L1 expression.

Overall, efti plus Keytruda achieved a 47% objective response rate in first-line NSCLC patients and 33% of the second-line HNSCC group, and median progression-free survival (PFS) hadn’t been reached at the data cut-off, more than seven months into the study.

Analyst Dr Chris Redhead at Goetzpartners said the data are encouraging and show the potential of efti – which targets lymphocyte activation gene-3 (LAG-3 or CD223) in combination with PD-1 inhibitor drugs.

The response rates for the combination with Keytruda are “on a par with the pembro-chemo combo [and] this potentially opens the door to a new effective first-line option”, he wrote in a research note, noting it could potentially sidestep the side effects seen with chemotherapy.

Immutep also has a phase 2b trial of efti ongoing – called AIPAC – that is testing the drug in combination with chemotherapy in metastatic breast cancer and could potentially support regulatory filings for the drug as a standalone immunotherapy.

Data is due in the next few weeks and if positive could “open the door to a substantial big pharma licensing deal”, says Redhead.

The PD-1/PD-L1 checkpoint inhibitors that hit the market in 2015 have already transformed the standard of care for some cancers, but there is still a sizeable patient population that doesn’t respond to them, and companies are seeking out new combinations that might improve results.

When given as a monotherapy, Keytruda’s benefits are mostly confined to the one-third or so of patients who have 50% or greater PD-L1 expression, says the Goetzpartners analyst, so “the results showing an almost 50% [response] across all patients at any level of PD-L1 expression are obviously extremely encouraging”.

Immutep seems to be slightly out in front among companies developing LAG-3-targeting drugs, but it has some heavyweight competition in the form of Merck, GlaxoSmithKline, Bristol-Myers Squibb and Regeneron, which all have candidates in clinical development.

Article by
Phil Taylor

21st February 2020

From: Research



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...